OICR and Johnson & Johnson Innovation (JLABS) have partnered on a joint symposium series, “Horizons and Controversies in Oncology” to bring together cancer researchers and industry professionals from across the world to learn about and discuss the latest in translational research.
Each quarterly event features a keynote address, lightning talks from industry/biotechs, a moderated panel discussion and audience Q&A.
June 1, 2021
Realizing the promise of cancer epigenetics
Dr. Andrew Paul Feinberg
Johns Hopkins University
Dr. Daniel De Carvalho
DNAMx and Princess Margaret Cancer Centre
Dr. Sarah Attwell
Event overview: Epigenetics is one of the most exciting fields in cancer research today and is revolutionizing how we understand and approach cancer. The study of DNA methylation and other epigenetic changes has vastly increased our knowledge of the role these processes play in cancer. This improved understanding is driving the development of a new class of therapies and tools that signal a new era in cancer prevention, screening, diagnosis, and care – areas in which Ontario is a world leader.
You’ll hear from leading researchers in this space to learn about the origins and rise of the field, where it is now and why there is so much enthusiasm for its potential. Our keynote speaker will be Dr. Andrew Paul Feinberg of Johns Hopkins University, who is considered to be the founder of the field of cancer epigenetics. Startups in the space, including Dr. Daniel De Carvalho, founder of DNAMx, and Dr. Sarah Attwell, Research Scientist at Zenith Epigenetics, will also share how they are capitalizing on these advancements and bringing transformative products to patients.
January 28, 2021
Cell therapy for cancer treatment: The past, present and future
Dr. James Yang
National Cencer Institute (Keynote)
Dr. Emily Titus
Dr. Michael Maguire
Event overview: Join the Ontario Institute for Cancer Research and JLABS for a deep dive into gene therapy, one of the most important advances in effectively treating and controlling diseases like cancer.
This program will cover where cell and gene therapy has been, where it’s going, and you’ll hear from startups on breakthrough technologies changing the future of this space. In a panel discussion following the presentations, experts will also debate the challenges and opportunities of applying different genetically-engineered cell therapy modalities to oncology.
About JLABS (https://jlabs.jnjinnovation.com/)
Johnson & Johnson Innovation – JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators across a broad healthcare spectrum including pharmaceutical, medical device, consumer and health tech sectors to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.